Syndesi Therapeutics SA

Public Biotech Stocks Bounce Forward And Back Again In the year to date the NASDAQ Biotech Index (NBI) has fallen by nearly 14% compared to the less risky NYSE Arca Pharmaceutical Index’s (DRG’s) fall

The US Federal Trade Commission has indicated that biopharma mergers would have a tougher time clearing the agency. But it’s decision not to intervene in Pfizer Inc. ’s $6.7bn acquisition of Arena P

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Continues Development Of Novel S

Halfway through February, seven different sources of funding for health care and life science innovations have announced newly raised pools of cash totaling $2.2bn for a wide array of technologies, in